EE186 Assessment of the Cost-Effectiveness of Secukinumab Versus Risankizumab for the Treatment of Adults With Moderate-to-Severe Plaque Psoriasis in the UK

Abstract

Authors

S Moreno S Walsh PJ Khanna M Jain N Tanova-Yotova

Full Text Cite This Article
Back to Volume 25, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×